Rhoen Klinikum AG

Rhoen Klinikum AG maintains a conservative capital structure with a debt-to-equity ratio of 0.09, significantly below the industry median, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 2.6, suggesting it can cover short-term obligations but with limited excess capacity. However, the company's cash and equivalents are negative at -47,000 EUR, which, when combined with long-term debt of 122,169,000 EUR, raises concerns about net cash position.

Profitability metrics show a return on equity (ROE) of 2.61% and a return on assets (ROA) of 1.89%, both below the industry median for healthcare facilities. This suggests that the company is generating relatively modest returns compared to its peers, despite maintaining a gross profit of 1,139,986,000 EUR on total revenue of 1,704,720,000 EUR. The operating margin is 2.4%, which is in line with the industry average, but the net margin of 2.02% is slightly below the median, indicating potential inefficiencies in cost management or tax strategy.

Geographically, Rhoen Klinikum AG is heavily concentrated in Germany, with the majority of its revenue derived from domestic operations. The company does not disclose significant international revenue, which limits its exposure to global market dynamics but also increases its vulnerability to domestic regulatory and economic shifts. Segment-wise, the company operates as a single integrated entity, with no material diversification across business lines, which could limit its ability to adapt to sector-specific disruptions.

Looking ahead, the company is projected to experience modest revenue growth, with a current fiscal year outlook of 1.2% and a next fiscal year outlook of 1.8%. These figures are in line with the broader healthcare sector's growth expectations, but the company's capital expenditure of -99,100,000 EUR suggests a focus on cost containment rather than expansion. The company's free cash flow is negative at -9,317,000 EUR, indicating that it is not generating sufficient cash from operations to fund its capital spending, which may require external financing or asset sales.

Risk factors include a medium liquidity risk due to the negative cash position and a low dilution risk, as the company has not issued additional shares recently. The risk assessment also highlights the potential for dilution if the company needs to raise capital to fund operations or expansion. The company's reliance on domestic operations and the regulatory environment in Germany could also pose operational and compliance risks. Analysts have assigned a mean recommendation of 2.67, which is a "Hold" rating, with no strong buy recommendations and only one buy recommendation, suggesting a cautious outlook.

Recent events include the publication of the latest financial report, which confirmed the company's financial position and strategic direction. No major regulatory changes or legal proceedings have been disclosed in the latest filings, and the company has not issued any significant press releases or investor updates in the past quarter.